Stephanie Niemi-Olson
Family · Tucson, AZNPI 1699191072
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,367 of the $14,722 with a category attached, or 70.4%. 34 manufacturers reported payments, led by TG Therapeutics, Inc. at 34.7% of the total. 2025 is the largest year on record at $6,401, 3.3 times the $1,917 reported in 2021. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 327 payments — averaging $45.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$5K
- Novartis$2K
- AbbVie$1K
- EMD Serono, Inc.$1K
- AstraZeneca$889
- Biogen$693
- plus $4K from 28 others
What the payments were for
- Consulting fees$4503%
- Speaking & faculty fees$3,86326%
- Food & beverage$10,36770%
- Education$420%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 17 | $5,102 |
| Novartis | 37 | $1,788 |
| AbbVie(2 entities) | 66 | $1,451 |
| EMD Serono, Inc. | 19 | $1,075 |
| AstraZeneca | 16 | $889 |
| Biogen | 13 | $693 |
| Biohaven Pharmaceuticals, Inc. | 28 | $548 |
| Pfizer | 13 | $501 |
| Biohaven Pharmaceutical Holding Company Ltd. | 36 | $455 |
| Amgen(2 entities) | 4 | $279 |
| UCB, Inc. | 8 | $206 |
| Bristol Myers Squibb | 10 | $196 |
| Lilly USA, LLC | 14 | $191 |
| Lundbeck LLC | 5 | $190 |
| Sanofi | 2 | $125 |
| SK Life Science, Inc. | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $122 |
| Vanda Pharmaceuticals Inc. | 4 | $106 |
| Argenx US, Inc. | 6 | $103 |
| Johnson & Johnson | 5 | $81 |
| Neurocrine Biosciences, Inc. | 4 | $79 |
| Genentech USA, Inc. | 4 | $76 |
| Genentech, Inc. | 1 | $69 |
| Boston Scientific | 1 | $52 |
| Cycle Pharmaceuticals Inc | 2 | $37 |
| Eisai Inc. | 2 | $35 |
| Impel Pharmaceuticals Inc. | 1 | $24 |
| Acadia Pharmaceuticals Inc | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Catalyst Pharmaceuticals, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,722 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VumerityDiroximel Fumarate | 33 | $340,921 |
| MayzentSiponimod | 16 | $238,765 |
| Nurtec OdtRimegepant Sulfate | 91 | $197,768 |
| BotoxOnabotulinumtoxina | 99 | $135,927 |
| PonvoryPonesimod | 11 | $108,245 |
| Aimovig AutoinjectorErenumab-Aooe | 79 | $88,456 |
| Teriflunomide | 25 | $84,300 |
| UbrelvyUbrogepant | 61 | $84,007 |
| Dimethyl Fumarate | 28 | $73,073 |
| Emgality PenGalcanezumab-Gnlm | 51 | $49,273 |
| FingolimodFingolimod Hcl | 41 | $31,405 |
| QuliptaAtogepant | 18 | $22,892 |
| KeppraLevetiracetam | 11 | $16,622 |
| RelpaxEletriptan Hydrobromide | 11 | $10,004 |
| RytaryCarbidopa/Levodopa | 12 | $5,066 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenVumerity | $693 | $340,92133 claims |
| AbbVieBotox, Ubrelvy, Qulipta | $1,451 | $242,826178 claims |
| NovartisMayzent | $1,788 | $238,76516 claims |
| PfizerNurtec Odt, Relpax | $501 | $207,772102 claims |
| Johnson & JohnsonPonvory | $81 | $108,24511 claims |
| Amneal Pharmaceuticals LLCRytary | $19 | $5,06612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Tucson
- Lindsay CarterTucson$108K
- Vicki McIntyreTucson$68K
- Amber KemnitzTucson$33K
- Joy BaynesTucson$30K
- Cynthia CarstenTucson$27K
- Sharon MorganTucson$22K
- Margaret SpencerTucson$19K
- Polina SamoylovaTucson$18K
- Cindy ChangTucson$14K
- Conrad CordovaTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.